Antibody-drug conjugate (ADC), which leverages the specificity of antibodies to couple STING agonists to tumor-specific antibodies, concentrates the payload on the tumor and is thus capable of reducing unnecessary exposure to normal tissue cells. This evidence concerns the gene STING1 and neoplasm.